All In Biotech

Free tool

FAERS Monitor: Xultophy 100/3.6

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 208583 or its brand name (Xultophy 100/3.6, Insulin Degludec, Liraglutide). Reports on generic versions are filed under their own applications.

Reports

1,658

Serious

1,268

76% of reports

Hospitalization

648

Death reported

90

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • blood glucose increased192
  • nausea122
  • acute kidney injury88
  • diarrhoea87
  • vomiting87
  • hypoglycaemia73
  • glycosylated haemoglobin increased62
  • lactic acidosis58
  • decreased appetite53
  • asthenia50
  • dizziness48
  • hyperglycaemia47
  • weight decreased44
  • blood glucose decreased43
  • hospitalisation43

Reports by year received

View as table
YearReports
20163
2017125
2018229
2019198
2020150
2021202
2022149
2023116
2024166
2025217
2026103

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,501 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
glycosylated haemoglobin increasedSignal6231.224.51,783
lactic acidosisSignal5822.817.71,184
hypoglycaemiaSignal7319.115.31,237
hyperglycaemiaSignal4716.412.4664
blood glucose increasedSignal19212.911.32,120
blood glucose decreasedSignal4311.48.5397
acute kidney injurySignal887.36.0475
hospitalisationSignal433.62.677
decreased appetiteSignal532.92.265
vomitingSignal872.31.967
weight decreased442.01.521
nausea1222.01.658
diarrhoea871.71.426
asthenia501.71.314
dizziness481.20.92

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.